The Application of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU

NCT ID: NCT06341062

Last Updated: 2025-02-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

44 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-15

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to quantitatively assess renal microcirculation changes by contrast-enhanced ultrasound and to obtain systemic hemodynamic information by ultrasound Doppler at the same time, to analyze the relationship between renal microcirculation changes and systemic hemodynamic changes, and to explore its predictive value in renal function recovery in patients with critical acute kidney injury. The main questions it aims to answer are:

1. To explore the quantitative parameters of contrast-enhanced ultrasound which can reflect the changes of renal microcirculation.
2. To explore the relationship between renal microcirculation and systemic hemodynamics.
3. To explore the value of renal microflow changes quantitatively evaluated by contrast-enhanced ultrasound in predicting renal function recovery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Quantitative analysis of cortical perfusion by contrast-enhanced ultrasound; Echocardiography; Quantitative results of renal artery and vein spectrum

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intensive Care Unit Acute Kidney Injury Ultrasound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients recovering before hospital discharge

Recovery is defined as a return to normal serum creatinine and urine volume or more than 50% improvement in serum creatinine and/or urine volume from baseline

No interventions assigned to this group

Patients not recovering before hospital discharge

Non-recovery is defined as no significant improvement or further increase in serum creatinine and/or urine volume, the need for dialysis, or death.

Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound

Intervention Type OTHER

Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound before hospital discharge

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound

Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound before hospital discharge

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years old;
* AKI was diagnosed \< 24 hours after first admission to intensive care unit (ICU) and the expected length of stay in ICU ≥48 hours;
* Meet Kidney Disease Improving Global Outcomes (KDIGO) 2012 diagnostic criteria for acute kidney injury;
* Contrast-enhanced ultrasound was performed within 24 hours after diagnosis of acute kidney injury (AKI).

Exclusion Criteria

* Known severe chronic kidney disease (CKD≥ stage 4) or undergoing hemodialysis treatment;
* Kidney transplantation or renal malignancy;
* Terminal stage of malignant tumor;
* Pregnancy;
* Renal artery stenosis or renal vein thrombosis;
* Allergy to contrast agent SonoVue(BraccoSpA, Milan, Italy) or its components, or the presence of severe cardiopulmonary insufficiency (e.g., right-to-left shunt heart disease or pulmonary systolic blood pressure \>90mmHg).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University Third Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cui Ligang

Chief Physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ligang Cui, Dr

Role: PRINCIPAL_INVESTIGATOR

Department of Ultrasound, Peking University Third Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Ultrasound Diagnosis, Peking University Third Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuewei Zhang, Dr

Role: CONTACT

18800109082

Ligang Cui, Dr

Role: CONTACT

13910627163

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ligang Cui

Role: primary

13910627163

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M2024078

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.